In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... Cramer has been grappling with is the direction Washington will take in the coming months.

The stock's rise snapped a four-day losing streak.

WASHINGTON (AP) — Federal officials on Thursday approved ... The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or ...

Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...

Sold by Vertex Pharmaceuticals in 50-milligram tablets as Journavx, suzetrigine is the first nonopioid painkiller to target pain-signaling pathways in the peripheral nervous system before those ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...

WASHINGTON (AP ... The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries. It’s the first ...

WASHINGTON — Federal officials on Thursday ... The Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.

WASHINGTON — Federal officials on Thursday ... treatment The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery ...